. "Kennedy, S. J." . . "Randomized, Placebo-Controlled Phase II Study of Vandetanib Plus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer" . "RIV/00843989:_____/07:00014903!RIV09-MZ0-00843989" . "Bodrogi, I." . "Journal of Clinical Oncology" . "Herbst, R. S." . . . . "Hou, J." . "0732-183X" . . . "receptor tyrosine kinase; malignant tumors; supportive care; solid tumors; trial; chemotherapy; gefitinib; erlotinib; bevacizumab; carboplatin"@en . "The activity of vandetanib plus docetaxel was assessed in patients with previously treated non-small-cell lung cancer (NSCLC) This two-part study comprised an open-label run-in phase and a double-blind randomized phase. Eligible patients had locally advanced or metastatic (stage IIIB/IV) NSCLC after failure of first-line platinum-based chemotherapy. The primary objective of the randomized phase was to prolong progression-free survival (PFS) in patients receiving vandetanib (100 or 300 mg/d) plus docetaxel (75 mg/m2 intravenous infusion every 21 days) versus placebo plus docetaxel. There was no statistically significant difference in overall survival among the three treatment arms. Common adverse events included diarrhea, rash, and asymptomatic prolongation of corrected QT (QTC) interval. The primary objective was achieved, with vandetanib 100 mg plus docetaxel demonstrating a significant prolongation of PFS compared with docetaxel in relation to the prespecified significance level."@en . "27" . . . "000251073200020" . "Gadgeel, S." . "US - Spojen\u00E9 st\u00E1ty americk\u00E9" . . "13"^^ . "RIV/00843989:_____/07:00014903" . . "Randomized, Placebo-Controlled Phase II Study of Vandetanib Plus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer"@en . "N, V" . . "Johnson, B. E." . . . "The activity of vandetanib plus docetaxel was assessed in patients with previously treated non-small-cell lung cancer (NSCLC) This two-part study comprised an open-label run-in phase and a double-blind randomized phase. Eligible patients had locally advanced or metastatic (stage IIIB/IV) NSCLC after failure of first-line platinum-based chemotherapy. The primary objective of the randomized phase was to prolong progression-free survival (PFS) in patients receiving vandetanib (100 or 300 mg/d) plus docetaxel (75 mg/m2 intravenous infusion every 21 days) versus placebo plus docetaxel. There was no statistically significant difference in overall survival among the three treatment arms. Common adverse events included diarrhea, rash, and asymptomatic prolongation of corrected QT (QTC) interval. The primary objective was achieved, with vandetanib 100 mg plus docetaxel demonstrating a significant prolongation of PFS compared with docetaxel in relation to the prespecified significance level." . "Randomizovan\u00E1 placebem kontrolovan\u00E1 f\u00E1ze II studie vandetanib plus docetaxel u pacient\u016F s nemalobun\u011B\u010Dnou plicn\u00ED rakovinou po selh\u00E1n\u00ED p\u0159edchoz\u00ED l\u00E9\u010Dby"@cs . "446396" . . "Roubec, Jarom\u00EDr" . . . . "Csada, E." . "Randomized, Placebo-Controlled Phase II Study of Vandetanib Plus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer"@en . "25" . . "1"^^ . "Aktivita vandetanibu s docetaxelem byla hodnocena u pacient\u016F po p\u0159edchoz\u00ED l\u00E9\u010Db\u011B pro nemalobun\u011B\u010Dn\u00FD plicn\u00ED karcinom ( NSCLC). Tato dvoud\u00EDln\u00E1 studie zahrnovala otev\u0159enou vstupn\u00ED \u010D\u00E1st a dvojit\u011B zaslepenou randomizovanou f\u00E1zi. Randomizov\u00E1ni byli pacienti s lok\u00E1ln\u011B pokro\u010Dil\u00FDm nebo metastatick\u00FDm (st\u00E1dium IIIB/IV) NSCLC po selh\u00E1n\u00ED prvn\u00ED linie chemoterapie s cisplatinou. Prim\u00E1rn\u00EDm c\u00EDlem pro randomizovanou f\u00E1zi bylo prodlou\u017Een\u00ED \u010Dasu do progrese ( PFS) u pacient\u016F l\u00E9\u010Den\u00FDch vandetanibem (100 nebo 300 mg/den) a docetaxelem ( 75 mg/m2 i.v. inf\u00FAzi ka\u017Ed\u00FDch 21 dn\u00ED) oproti placebu s docetaxelem. Nebyl zji\u0161t\u011Bn \u017E\u00E1dn\u00FD statisticky signifikantn\u00ED rozd\u00EDl v celkov\u00E9m p\u0159e\u017Eit\u00ED mezi v\u0161emi t\u0159emi rameny. Obecn\u00FDmi ne\u017E\u00E1douc\u00EDmi \u00FA\u010Dinky byl pr\u016Fjem, rash, asymtpomatick\u00E9 prodlou\u017Een\u00ED korigovan\u00E9ho QT (QTC) intervalu. Prim\u00E1rn\u00ED c\u00EDl byl dosa\u017Een v rameni s vandetanibem 100 mg a docetaxelem v signifikantn\u00EDm prodlou\u017Een\u00ED \u010Dasu do progrese ve srovn\u00E1n\u00ED se samotn\u00FDm docetaxelem."@cs . "[54287826F7EA]" . "Randomizovan\u00E1 placebem kontrolovan\u00E1 f\u00E1ze II studie vandetanib plus docetaxel u pacient\u016F s nemalobun\u011B\u010Dnou plicn\u00ED rakovinou po selh\u00E1n\u00ED p\u0159edchoz\u00ED l\u00E9\u010Dby"@cs . . "Prager, D." . "Heymach, J. V." . "Randomized, Placebo-Controlled Phase II Study of Vandetanib Plus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer" . . "Belani, Ch.P." . "\u0160p\u00E1sov\u00E1, I." . "8"^^ . . "Pe\u0161ek, M." .